tcsc0594 NVP-TAE 226

NVP-TAE 226 is a dual tyrosine kinase inhibitor of FAK (IC₅₀=5.5 nM) and IGF-IR (mean IC₅₀=0.14 μM).

IC50 & Target: IC50: 5.5 nM (FAK), 3.5 nM (Pyk2), 0.14 μM (IGF-IR), 0.16 μM (c-Met), 0.36 μM (KDR), 0.48 μM (Flt3)^[1]

In Vitro: NVP-TAE 226 (TAE226), a potent ATP-competitive inhibitor of several tyrosine protein kinases, in particular FAK and IGF-IR kinases. In a cell-based kinase assays, FAK, IGF-IR kinase, and IR kinase are inhibited with an IC₅₀ range of 100 to 300 nM compared with the other kinases tested, which are >10-fold less sensitive. In culture, NVP-TAE 226 inhibits extracellular matrix-induced autophosphorylation of FAK (Tyr³⁹⁵). NVP-TAE 226 also inhibits IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt. NVP-TAE 226 retards tumor cell growth as assessed by a cell viability assay and attenuates G₂-M cell cycle progression associated with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr¹⁵) protein expression. NVP-TAE 226 treatment inhibits tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay. Interestingly, TAE226 treatment of tumor cells containing wild-type p53 mainly exhibits G₂-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis^[1].

In Vivo: Treatment with NVP-TAE 226 (TAE226) at 50 or 75 mg/kg extends the median survival of U87 xenograft animals by 6 and 7 days, respectively (P=0.084 and P=0.042, respectively, compared with vehicle-treated animals). However, NVP-TAE 226 treatment of LN229-engrafted animals significantly prolongs their median survival by 19 days (P<0.004 for both dosages, compared with vehicle-treated animals)^[1].